We are inspired by the story of repurposing the kidney cancer drug sunitinib or sutent (DB01268) for treating acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients[18,19,20] by antagonizing the elevated activity of FMS-like tyrosine kinase-3 (FLT3) present in a rare form of ALL patients. The gene discussed is FLT3; the disease is kidney cancer.